INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patient is currently benefiting from the treatment │ Patient is currently benefiting from the treatment │     100 │
│ with pasireotide, as determined by the             │ with pasireotide, as determined by the             │         │
│ investigator                                       │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has demonstrated compliance, as assessed   │ Patient has demonstrated compliance, as assessed   │     100 │
│ by the investigator, with the parent study         │ by the investigator, with the parent study         │         │
│ requirements                                       │ requirements                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Willingness and ability to comply with scheduled   │ Willingness and ability to comply with scheduled   │     100 │
│ visits, treatment plans and any other study        │ visits, treatment plans and any other study        │         │
│ procedures                                         │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has been permanently discontinued from     │ Patient has been permanently discontinued from     │     100 │
│ pasireotide study treatment in the parent study    │ pasireotide study treatment in the parent study    │         │
│ due to unacceptable toxicity, non-compliance to    │ due to unacceptable toxicity, non-compliance to    │         │
│ study procedures, withdrawal of consent or any     │ study procedures, withdrawal of consent or any     │         │
│ other reason                                       │ other reason                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or nursing (lactating) women, where       │ Pregnant or nursing (lactating) women, where       │     100 │
│ pregnancy is defined as the state of a female      │ pregnancy is defined as the state of a female      │         │
│ after conception and until the termination of      │ after conception and until the termination of      │         │
│ gestation, confirmed by a positive hCG laboratory  │ gestation, confirmed by a positive hCG laboratory  │         │
│ test                                               │ test                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female sterilization (have had surgical bilateral  │ Female sterilization (have had surgical bilateral  │     100 │
│ oophorectomy with or without hysterectomy) or      │ oophorectomy with or without hysterectomy) or      │         │
│ tubal ligation at least six weeks before taking    │ tubal ligation at least six weeks before taking    │         │
│ study treatment. In case of oophorectomy alone,    │ study treatment. In case of oophorectomy alone,    │         │
│ only when the reproductive status of the woman has │ only when the reproductive status of the woman has │         │
│ been confirmed by follow up hormone level          │ been confirmed by follow up hormone level          │         │
│ assessment                                         │ assessment                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of oral, injected or implanted hormonal        │ Use of oral, injected or implanted hormonal        │      86 │
│ methods of contraception or placement of an        │ methods of contraception or other forms of         │         │
│ intrauterine device (IUD) or intrauterine system   │ hormonal contraception that have comparable        │         │
│ (IUS), or other forms of hormonal contraception    │ efficacy (failure rate <1%), for example hormone   │         │
│ that have comparable efficacy (failure rate \<1%), │ vaginal ring or transdermal hormone contraception  │         │
│ for example hormone vaginal ring or transdermal    │                                                    │         │
│ hormone contraception                              │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male sterilization (at least 6 months prior to     │ Male sterilization (at least 6 months prior to     │      92 │
│ enrolling). For female patients on the study the   │ screening). For female subjects on the study the   │         │
│ vasectomized male partner should be the sole       │ vasectomized male partner should be the sole       │         │
│ partner for that patient                           │ partner for that subject                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Total abstinence (when this is in line with the    │ Total abstinence (when this is in line with the    │      98 │
│ preferred and usual lifestyle of the patient.      │ preferred and usual lifestyle of the subject.      │         │
│ Periodic abstinence (e.g., calendar, ovulation,    │ Periodic abstinence (e.g., calendar, ovulation,    │         │
│ symptothermal, post-ovulation methods) and         │ symptothermal, post-ovulation methods) and         │         │
│ withdrawal are not acceptable methods of           │ withdrawal are not acceptable methods of           │         │
│ contraception                                      │ contraception                                      │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ Patient has demonstrated compliance, as assessed   │      29 │
│                                                    │ by the investigator, with the parent study         │         │
│                                                    │ requirements                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of child-bearing potential, defined as all   │ Patient has participated in a Novartis sponsored   │      44 │
│ women physiologically capable of becoming          │ combination trial where pasireotide was dispensed  │         │
│ pregnant, unless they are using highly effective   │ in combination with another study medication and   │         │
│ methods of contraception during the study          │ is still receiving combination therapy. (only      │         │
│ treatment and for 30 days after the final dose of  │ patients receiving pasireotide monotherapy can be  │         │
│ pasireotide s.c. and 84 days after the final dose  │ included)                                          │         │
│ of pasireotide LAR. Highly effective contraception │                                                    │         │
│ is defined as either                               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Written informed consent obtained prior to         │ Written informed consent obtained prior to         │      60 │
│ enrolling in roll-over study and receiving study   │ enrolling in roll-over study and receiving study   │         │
│ medication                                         │ medication • If consent cannot be expressed in     │         │
│                                                    │ writing, it must be formally documented and        │         │
│                                                    │ witnessed, ideally via an independent trusted      │         │
│                                                    │ witness                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women are considered post-menopausal and not of    │ Female sterilization (have had surgical bilateral  │      62 │
│ child bearing potential if they have had 12 months │ oophorectomy with or without hysterectomy) or      │         │
│ of natural (spontaneous) amenorrhea with an        │ tubal ligation at least six weeks before taking    │         │
│ appropriate clinical profile (i.e. age             │ study treatment. In case of oophorectomy alone,    │         │
│ appropriate, history of vasomotor symptoms) or     │ only when the reproductive status of the woman has │         │
│ have had surgical bilateral oophorectomy (with or  │ been confirmed by follow up hormone level          │         │
│ without hysterectomy), total hysterectomy, or      │ assessment                                         │         │
│ tubal ligation at least six weeks ago. In the case │                                                    │         │
│ of oophorectomy alone, only when the reproductive  │                                                    │         │
│ status of the woman has been confirmed by follow   │                                                    │         │
│ up hormone level assessment is she considered not  │                                                    │         │
│ of child-bearing potential                         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Sexually active males, unless they use a condom    │ Sexually active males unless they use a condom     │      62 │
│ during intercourse while taking drug and for 1     │ during intercourse while taking drug and for 1     │         │
│ months after pasireotide s.c. last dose and 3      │ months after pasireotide s.c. last dose and 3      │         │
│ months after pasireotide LAR last dose, should not │ months after pasireotide LAR last dose and should  │         │
│ father a child in this period. A condom is         │ not father a child in this period. A condom is     │         │
│ required to be used also by vasectomized men in    │ required to be used also by vasectomized men in    │         │
│ order to prevent delivery of the drug via seminal  │ order to prevent delivery of the drug via seminal  │         │
│ fluid                                              │ fluid If a study patient or partner becomes        │         │
│                                                    │ pregnant or suspects being pregnant during the     │         │
│                                                    │ study or within 1 month after the final dose of    │         │
│                                                    │ pasireotide s.c. or 3 months after the final dose  │         │
│                                                    │ of pasireotide LAR, the Study Doctor needs to be   │         │
│                                                    │ informed immediately and ongoing study treatment   │         │
│                                                    │ with pasireotide has to be stopped immediately For │         │
│                                                    │ patients taking pasireotide LAR, the future dose   │         │
│                                                    │ injections will be cancelled                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In case of use of oral contraception women should  │ Barrier methods of contraception: Condom or        │      65 │
│ have been stable on the same pill for a minimum of │ Occlusive cap diaphragm or cervical/vault caps)    │         │
│ 3 months before taking study treatment             │ with spermicidal foam/gel/film/cream/vaginal       │         │
│                                                    │ suppository In case of use of oral contraception   │         │
│                                                    │ women should have been stable on the same pill for │         │
│                                                    │ a minimum of 3 months before taking study          │         │
│                                                    │ treatment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If consent cannot be expressed in writing, it must │ Written informed consent obtained prior to         │      71 │
│ be formally documented and witnessed, ideally via  │ enrolling in roll-over study and receiving study   │         │
│ an independent trusted witness                     │ medication • If consent cannot be expressed in     │         │
│                                                    │ writing, it must be formally documented and        │         │
│                                                    │ witnessed, ideally via an independent trusted      │         │
│                                                    │ witness                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently participating in a Novartis-  │ Patient is currently participating in a Novartis   │      78 │
│ sponsored study receiving pasireotide (LAR and/or  │ Oncology sponsored study receiving pasireotide     │         │
│ s.c.) on monotherapy or combination therapy (for   │ (LAR and/or s.c.) and has fulfilled all required   │         │
│ Cushing's Disease or Acromegaly), and has          │ assessments in the parent study (unless the study  │         │
│ fulfilled all required assessments in the parent   │ is being terminated) and patients that are         │         │
│ study and patients that are benefiting from the    │ benefiting from the study drug have no other       │         │
│ study treatment have no other alternatives         │ alternatives                                       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patient has demonstrated compliance, as assessed   │ Placement of an intrauterine device (IUD) or       │      41 │
│ by the investigator, with the parent study         │ intrauterine system (IUS)                          │         │
│ requirements                                       │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently participating in a Novartis-  │ Patient has participated in a Novartis sponsored   │      53 │
│ sponsored study receiving pasireotide (LAR and/or  │ combination trial where pasireotide was dispensed  │         │
│ s.c.) on monotherapy or combination therapy (for   │ in combination with another study medication and   │         │
│ Cushing's Disease or Acromegaly), and has          │ is still receiving combination therapy. (only      │         │
│ fulfilled all required assessments in the parent   │ patients receiving pasireotide monotherapy can be  │         │
│ study and patients that are benefiting from the    │ included)                                          │         │
│ study treatment have no other alternatives         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Sexually active males, unless they use a condom    │ Sexually active males unless they use a condom     │      62 │
│ during intercourse while taking drug and for 1     │ during intercourse while taking drug and for 1     │         │
│ months after pasireotide s.c. last dose and 3      │ months after pasireotide s.c. last dose and 3      │         │
│ months after pasireotide LAR last dose, should not │ months after pasireotide LAR last dose and should  │         │
│ father a child in this period. A condom is         │ not father a child in this period. A condom is     │         │
│ required to be used also by vasectomized men in    │ required to be used also by vasectomized men in    │         │
│ order to prevent delivery of the drug via seminal  │ order to prevent delivery of the drug via seminal  │         │
│ fluid                                              │ fluid If a study patient or partner becomes        │         │
│                                                    │ pregnant or suspects being pregnant during the     │         │
│                                                    │ study or within 1 month after the final dose of    │         │
│                                                    │ pasireotide s.c. or 3 months after the final dose  │         │
│                                                    │ of pasireotide LAR, the Study Doctor needs to be   │         │
│                                                    │ informed immediately and ongoing study treatment   │         │
│                                                    │ with pasireotide has to be stopped immediately For │         │
│                                                    │ patients taking pasireotide LAR, the future dose   │         │
│                                                    │ injections will be cancelled                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In case of use of oral contraception women should  │ Barrier methods of contraception: Condom or        │      65 │
│ have been stable on the same pill for a minimum of │ Occlusive cap diaphragm or cervical/vault caps)    │         │
│ 3 months before taking study treatment             │ with spermicidal foam/gel/film/cream/vaginal       │         │
│                                                    │ suppository In case of use of oral contraception   │         │
│                                                    │ women should have been stable on the same pill for │         │
│                                                    │ a minimum of 3 months before taking study          │         │
│                                                    │ treatment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If consent cannot be expressed in writing, it must │ Written informed consent obtained prior to         │      71 │
│ be formally documented and witnessed, ideally via  │ enrolling in roll-over study and receiving study   │         │
│ an independent trusted witness                     │ medication • If consent cannot be expressed in     │         │
│                                                    │ writing, it must be formally documented and        │         │
│                                                    │ witnessed, ideally via an independent trusted      │         │
│                                                    │ witness                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient is currently participating in a Novartis-  │ Patient is currently participating in a Novartis   │      78 │
│ sponsored study receiving pasireotide (LAR and/or  │ Oncology sponsored study receiving pasireotide     │         │
│ s.c.) on monotherapy or combination therapy (for   │ (LAR and/or s.c.) and has fulfilled all required   │         │
│ Cushing's Disease or Acromegaly), and has          │ assessments in the parent study (unless the study  │         │
│ fulfilled all required assessments in the parent   │ is being terminated) and patients that are         │         │
│ study and patients that are benefiting from the    │ benefiting from the study drug have no other       │         │
│ study treatment have no other alternatives         │ alternatives                                       │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 74
Average Levenshtein Ratio of individual lines: 74.65217391304348
OverAll Ratio: 74.32608695652175
